BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance
The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.
Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy
Recently, BEAM reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. Unfortunately, they concurrently announced a $500 million equity offering, which may have caused concerns about near-term dilution. Still, BEAM-302 has innovative in vivo base editing technology that could potentially offer a one-time curative therapy for patients suffering from AATD.
BEAM Down Despite Positive Initial Data From Genetic Disorder Study
Beam Therapeutics posts positive initial data from a phase I/II study investigating BEAM-302 for treating alpha-1 antitrypsin deficiency.
Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates
BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to earnings of $1.73 per share a year ago.
Wall Street Analysts See a 67.27% Upside in Beam Therapeutics (BEAM): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 67.3% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year?
Here is how Beam Therapeutics Inc. (BEAM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.
Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 84.45%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 84.5% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is it a Good Idea to Invest in Beam Therapeutics Stock Now?
Here, we discuss some reasons why investing in BEAM stock now may turn out to be a prudent move.
Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now?
Beam Therapeutics (BEAM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
2 Stocks for Bulls This Year: Beam Therapeutics, Bloom Energy
Beam Therapeutics (BEAM) Gene editing firm Beam Therapeutics is developing its own pipeline with base editing as its foundation technology, a technique that changes a single DNA or RNA base without cutting the DNA strand.
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up
BEAM appoints Sravan K. Emany as its new chief financial officer, effective Dec. 19.
